{
  "symbol": "CRSP",
  "company": "CRISPR Therapeutics AG",
  "generated_at": "2026-06-24T07:36:46.794Z",
  "event_count": 2,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T13:10:56.751Z",
      "summary": "CRSP is a pre-revenue gene editing biotech with one approved therapy (CASGEVY, partnered to Vertex) and multiple pipeline programs in various stages of development. The company burns ~$130M/quarter in cash while generating minimal collaboration revenue ($1-4M/quarter). CASGEVY uptake has been slower than expected per Vertex's guidance, limiting near-term royalty upside for CRSP. The stock trades 27% off its 52-week high and is approaching that range ceiling after a +9% single-day surge on June 5 (likely triggered by Eli Lilly competitive data news re-framing the sector narrative). No open-market insider purchases were detected in the trailing period — all recent Form 4s reflect RSU grants to executives, not buys. There are upcoming binary catalysts including zugo-cel autoimmune Phase 1/2 data and CTX310 Phase 1b readout expected H2 2026, but these are speculative outcomes with no confirmed timing. The balance sheet shows $2.44B in cash against ~$585M in long-term debt; runway extends to approximately mid-2027 at current burn rates without additional partnership payments. No clear mispricing relative to biotech peers given the pre-profitability status and negative FCF.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 20,
      "walltime_min": 22,
      "debug_path": "dossiers/2026-06-05-CRSP.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-09T03:42:39.133Z",
      "summary": "CRISPR Therapeutics is a pre-commercial gene-editing biotech whose sole approved product CASGEVY (co-commercialized with Vertex) showed weak Q1 2026 results — EPS missed by -12.4%, revenue by -82.6%. A $700M convertible notes offering in March 2026 further diluted shareholders without resolving the fundamental burn problem (~-$260M FCF annually). No open-market insider purchases from CEO/CFO exist in recent filings; Form 4 activity reflects RSU vesting and option exercises only, not directional conviction buys. Options flow is put-heavy (PC ratio 1.31) with no whale blocks, technicals show the stock below its 200DMA after falling ~30% from October 2025 highs near $77 to current ~$55. No named catalyst in the 3-12 month window that would force a re-rating — pipeline programs are 2-4 years from approval and market already appears to be discounting significant CASGEVY commercial uptake that has not materialized.",
      "verdict": "no_anomaly",
      "confidence": 5,
      "tool_calls": 17,
      "walltime_min": 11,
      "debug_path": "dossiers/2026-05-09-CRSP.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "CRSP",
    "call": "HOLD",
    "confidence": 3,
    "score": 1,
    "factors": {
      "below_200dma": "-2",
      "above_50dma": "+1",
      "momentum_flat": "0 (6.7%)",
      "rsi_neutral": "0 (54.4)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (3d ago)",
      "from_high": "0 (-29.7%)"
    },
    "summary": "HOLD (score +1) · 12-1 mom 6.7% · RSI 54.4 · above_50_only · -29.7% from high",
    "last_close": 53.99,
    "one_month_ago_close": 49.9,
    "twelve_month_ago_close": 46.78,
    "twelve_one_momentum_pct": 6.67,
    "rsi_14": 54.4,
    "ma_stack": "above_50_only",
    "from_period_high_pct": -29.68,
    "period_high": 76.78,
    "price_targets": {
      "bear": 44,
      "fair": 63.45,
      "bull": 291,
      "bear_return_pct": -18.5,
      "fair_return_pct": 17.5,
      "bull_return_pct": 439,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 44,
        "target_mean": 83.52381,
        "target_high": 291,
        "analyst_count": 21
      }
    },
    "generated_at": "2026-06-24T07:36:46.790Z"
  }
}